Lin Bioscience Inc
TPEX:6696
Decide a qué precio te sentirías cómodo comprando y te ayudaremos a estar preparado.
|
L
|
Lin Bioscience Inc
TPEX:6696
|
TW |
|
P
|
Promact Impex Ltd
BSE:526494
|
IN |
|
A
|
Avenir Telecom SA
LSE:0DO7
|
FR |
Valor intrínseco
No hay suficientes datos para calcular de forma fiable el valor intrínseco de Lin Bioscience Inc.
¿Nuestras valoraciones funcionan de verdad? Ver resultados del backtest .
Análisis fundamental
Qué hace Lin Bioscience
Lin BioScience, Inc. engages in the development of drugs. The company is headquartered in Taipei City, Taipei. The company went IPO on 2018-10-08. The firm is in the research and development and clinical trials stage. The company has four major drugs in development, including LBS-008, LBS-007, LBS-009 and LBS-002, as well as two technical platforms of RBP4 and CDC7. LBS-008 is developed for dry macular degeneration which belongs to the best-selling drugs, and stel lesions which belongs to orphan drugs.
- Sede central
- Taiwán TW
- Fecha de salida a bolsa
- 8 oct., 2018